ESTRO 2022 - Abstract Book

S1142

Abstract book

ESTRO 2022

A small subject of carefully selected patients despite their advanced disease shows good response to palliative hypo- fractionated radiotherapy. In these further radiation by means of external beam radiotherapy or brachytherapy can be contemplated with satisfactory results.

PO-1347 Which Is The Best Time To Assess Complete Response After Chemoradiation In Advanced Cervical Cancer?

R. AUTORINO 1 , V. Lancellotta 1 , M. Campitelli 1 , A. Nardangeli 1 , L. Russo 2 , R.M. Rinaldi 1 , N. Bizzarri 3 , B. Gui 2 , V. Rufini 2 , M.G. Ferrandina 4 , G. Macchia 5 , M.A. Gambacorta 1 , V. Valentini 1 1 UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy; 2 Radiology, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy; 3 Gynecological Oncology, Department of Woman and Child Health and Public Health, Woman Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Rome, Italy; 4 Gynecologic Oncology, Department of Woman and Child Health and Public Health, Woman Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 5 Radiation Oncology Unit, Gemelli Molise Hospital, Università Cattolica del Sacro Cuore, Campobasso, Italy Purpose or Objective The assessment of clinical response after exclusive chemoradiation in locally advanced cervical cancer (LACC) is recommended 3-6 months following completion of treatment, as per international guidelines. Aim of the present study was to investigate the best timepointfor assessing the clinical complete response in our series of LACC patients. Materials and Methods atients with histologically proven squamous cell cervical cancer or adenocarcinoma, stage IB2-IVA FIGO 2018 were retrospectively analyzed. All patients received intravenous cisplatin (40 mg/m ² /weekly), external beam radiotherapy (45 Gy in 25 daily fractions ± simultaneous lymph-nodes boost) and interventional radiotherapy (IRT, 28 Gy/twice/weekly). The primary endpoint was complete response evaluation, that we analysed at three timepoints with magnetic resonance imaging: 1) Assessment 1: At the end of external beam radiotherapy, before IRT (5-6 weeks from the start of treatment) Results 63 patients (median age: 55 years; 2018 FIGO stage IA: 1, IIA: 3, IIB: 15; IIIA: 1; IIIC1: 29; IIIC2: 10; IVA: 3; IVB:1) were analyzed. 57 patients had a squamous cell carcinoma, 6 adenocarcinoma. The treatment was well tolerated with a satisfactory compliance. Complete clinical response was achieved in 16 patients at assessment 1, 42 of patients at assessment 2, and 47 of patients at assessment 3. Seven Patients (53%) with a partial response at assessment 2 had a complete response at 6 months from the end of the treatment. Nine patients were missing at the third assessment. Six months after treatment 80% of clinical complete response was registered (Fig. 1). We have a significative correlation with global overall survival at all assessments (Fig. 2).Fig 1. 2) Assessment 2: 3 months after the end of IRT (18-20 weeks from the start of treatment) 3) Assessment 3: 6 months after the end of IRT (30-32 weeks from the start of treatment)